Although assessment of segregation does not support pathogenicity, the identification of this substitution in five MS families and no controls warrants further studies to elucidate whether RNF213 p.Arg4019Cys causes a low-penetrance phenotype with a clinical presentation of MS. Here, RNF213 is linked to myeloid sarcoma.